Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Appointed director
CC transcript
NPS PHARMACEUTICALS INC (NPSP) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/23/2015 8-K Form 8-K - Current report
01/12/2015 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Agreement and Plan of Merger, among NPS Pharmaceuticals, Inc., Shire Pharmaceutical Holdings Ireland Limited, Knight Newco 2, Inc. and Shire plc",
"Amended and Restated Bylaws of NPS Pharmaceuticals, Inc",
"Change in Control Severance Pay Plan, as amended on January 11, 2015",
"Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech"
11/10/2014 8-K Quarterly results
Docs: "NPS Pharma Reports Third-Quarter 2014 Financial Results Net global Gattex®/Revestive® sales of $28 million representing sequential growth of 28 percent Company on track to meet full-year financial guidance"
11/04/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "NPS Pharma Appoints Pierre Legault to Board of Directors"
09/12/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of Hypoparathyroidism NPS Pharma to host conference call today at 5:30 PM EDT PDUFA date for Natpara BLA is October 24, 2014"
08/06/2014 8-K Quarterly results
Docs: "NPS Pharma Reports Second-Quarter 2014 Financial Results Net global Gattex®/Revestive® sales of $22 million representing sequential growth of 22 percent Full-year sales on track to meet guidance of $100 to $110 million"
06/10/2014 8-K Other Events
06/02/2014 8-K Regulation FD Disclosure
05/08/2014 8-K Quarterly results
Docs: "NPS Pharma Reports First-Quarter 2014 Financial Results Net global Gattex®/Revestive® sales of $18 million representing 17 percent sequential growth"
05/07/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "NPS Pharmaceuticals, Inc. 2014 Omnibus Equity Compensation Plan",
"Form of Incentive Stock Option Award Agreement",
"Form of Nonqualified Stock Option Award Agreement",
"Form of Restricted Stock Unit Award Agreement",
"NPS Pharmaceuticals, Inc. Deferred Compensation Plan"
03/05/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/18/2014 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014"
01/08/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "NPS Pharmaceuticals Reports Preliminary 2013 Results and 2014 Financial Outlook"
12/23/2013 8-K Entry into a Material Definitive Agreement
12/19/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/06/2013 8-K Form 8-K - Current report
08/08/2013 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Second Quarter 2013 Financial Results and Provides Business Update"
06/21/2013 8-K Results of Operations and Financial Condition
05/09/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2005 Omnibus Incentive Plan of NPS Pharmaceuticals, Inc., as amended and restated through May 7, 2013"
05/09/2013 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports First Quarter 2013 Financial Results"
03/19/2013 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "Termination and Transition Agreement, by and among Takeda GmbH, Takeda Pharma A/S and the Company",
"NPS Pharmaceuticals and Takeda Revise Agreements and NPS Re-Gains Full Worldwide Rights to Teduglutide and Recombinant Human Parathyroid Hormone 1-84"
02/21/2013 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports 2012 Financial Results and 2013 Guidance"
11/09/2012 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Third Quarter 2012 Financial Results and Reiterates Year-end Cash Guidance -- FDA Advisory Committee unanimously recommends approval of Gattex® for adult patients with short bowel syndrome -- -- One out of seven patients has now achieved independence from PN/IV fluids in ongoing STEPS 2 study -- -- Conference call today at 8:30 AM ET --"
08/01/2012 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Second Quarter 2012 Financial Results"
07/02/2012 8-K Form 8-K - Current report
05/21/2012 8-K Submission of Matters to a Vote of Security Holders
05/03/2012 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports First Quarter 2012 Financial Results -- Four additional patients weaned off parental nutrition and IV fluids while receiving Gattex therapy in ongoing STEPS 2 open-label extension study -- -- Results of Phase 3 REPLACE registration study of Natpara ® accepted for oral presentation at the annual meeting of The Endocrine Society in June -- -- Conference call today at 5:00 PM ET --"
02/29/2012 8-K Form 8-K - Current report
11/07/2011 8-K Form 8-K - Current report
11/03/2011 8-K Quarterly results
Docs: "NPS Pharmaceuticals Reports Third Quarter 2011 Financial Results and Improves Cash Burn Guidance"
10/31/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "Phase 3 GATTEX® Data Highlight Potential New Treatment for Adults with Short Bowel Syndrome Four abstracts, including new data from STEPS 2, presented at American College of Gastroenterology Annual Scientific Meeting"
08/15/2011 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Fourth Amendment to the Development and License Agreement as amended between the Company and Amgen",
"NPS Pharmaceuticals Announces Amended Amgen Agreement and Plan to Retire Sensipar-Backed Series B Notes"
08/02/2011 8-K Form 8-K - Current report
05/24/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy